StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $8.17 | $8.13 | -0.49% | 0.0M |
| 05-12 | $8.12 | $8.10 | -0.25% | 0.0M |
| 05-13 | $8.05 | $8.02 | -0.37% | 0.0M |
| 05-14 | $8.16 | $8.04 | -1.47% | 0.0M |
| 05-15 | $8.14 | $8.07 | -0.86% | 0.0M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2021 2021-12-31 | Q3 2021 2021-09-30 | Q2 2021 2021-06-30 | Q1 2021 2021-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-155.56M | $-101.81M | $-58.78M | $-23.40M |
Net Income | $-156.79M | $-101.44M | $-35.31M | $-23.13M |
EPS (Diluted) | $-1.48 | $-1.03 | $-0.71 | $-0.66 |
Total Assets | $609.98M | $647.40M | $672.67M | $696.14M |
Total Liabilities | $54.78M | $45.98M | $37.20M | $30.99M |
Cash & Equivalents | $37.59M | $20.40M | $566.73M | $609.64M |
Free Cash Flow OCF − CapEx | $-179.97M | $-118.72M | $-67.58M | $-26.86M |
Shares Outstanding | 129.03M | 128.86M | 128.74M | 128.74M |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.